Clinical trial · Observational
SMC Radiation Oncology SABR Cohort for Oligometastasis
Cohort Study for Local Stereotactic Body Radiotherapy in Patients With Oligometastatic or Oligoprogressive Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1. oncologic outcomes (progression-free survival, local failure rate), 2. patient-reported outcomes, 3. physician-assessed toxicity, and 4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| ctDNA | — | UNRESOLVED | — |
| Oligometastasis | — | UNRESOLVED | — |
| Oligoprogression | — | UNRESOLVED | — |
| Patient-Reported Outcomes (PRO) | — | UNRESOLVED | — |
| Stereotactic Body Radiation Therapy (SBRT) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stereotactic body radiotherapy (SBRT) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Progression-free survival
- timeFrame
- From start of SABR to the earliest of local failure, distant failure, death, or last follow-up. It will be measured at 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.
- description
- Time from the start of stereotactic body radiotherapy (SABR) to the first documented event of local failure, distant failure, death from any cause, or last follow-up, whichever occurs first.
- measure
- Physician assessed toxicity
- timeFrame
- 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.
- description
- Evaluated by treating physician based on CTCAE ver 5.0
- measure
- Patient-reported outcome
- timeFrame
- 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.
- description
- It will be measured by PRO-CTCAE coreset 12.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Performance status (ECOG PS) 0-2 * Diagnosed with metastatic disease * Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions) Exclusion Criteria: * Patient with a history of prior radiotherapy to the site planned for SABR * Patients with concomitant brain metastases
References
Publications (0)
Data not yet available